A Novel Anti-CD40 Monoclonal Antibody, Iscalimab, for Control of Graves Hyperthyroidism—A Proof-of-Concept Trial
Новый моноклональный антитело против CD40 — исцалимаб — для контроля гипертиреоза при болезни Грейвса: доказательное исследование
2019-09-12
SCID: 54.1/49ctgasj
Discuss with AI
CD40-CD154 co-stimulatory pathwayGraves diseaseIscalimabanti-CD40 monoclonal antibodyphase II proof-of-concept trial
Figures from the paper
Abstract (AI)
CONTEXT: The CD40-CD154 co-stimulatory pathway plays an important role in the pathogenesis of Graves disease (GD) by promoting autoreactive B-cell activation. OBJECTIVE: Evaluate efficacy and safety of a human, blocking, nondepleting anti-CD40 monoclonal antibody, iscalimab, in hyperthyroid patients with GD. DESIGN: Open-label, phase II proof-of-concept study. SETTING: Multicenter. PATIENTS: Fifteen with GD. INTERVENTION: Patients received 5 doses of iscalimab at 10 mg/kg intravenously over 12 weeks. MAIN OUTCOME MEASURES: Thyroid-related hormones and autoantibodies, plasma soluble CD40, free CD40 on B cells, soluble CXCL13, pharmacokinetics, and safety were assessed. RESULTS: The iscalimab intervention resulted in complete CD40 engagement for up to 20 weeks. A clinical response and biochemical euthyroidism was observed in 7 of 15 (47%) patients. Free and total triiodothyronine and thyroxine normalized in 7 patients who did not receive any rescue medication with antithyroid drugs (ATD), and 2/15 (13.3%) showed normal thyrotropin. Six (40%) patients required ATD. Four of 7 responders relapsed after treatment completion. Serum concentrations of thyrotropin receptor autoantibodies (TSH-R-Ab) significantly declined in all patients (mean 15.3 IU/L vs 4.0 IU/L, 66% reduction; P < 0.001) and TSH-R-Ab levels normalized in 4 (27%). Thyroperoxidase and thyroglobulin autoantibodies significantly decreased in responders. Iscalimab rapidly reduced serum CXCL13 concentrations (P < 0.001). Twelve (80.0%) patients reported at least 1 adverse event (AE). All treatment-related AE were mild or moderate and resolved by end of the study. CONCLUSION: Iscalimab was generally safe and clinically effective in a subgroup of hyperthyroid GD patients. The potential therapeutic benefit of iscalimab should be further tested.
Key Findings
1
Four of the seven initial responders relapsed after treatment completion, indicating incomplete durability of response.
2
In an open-label phase II study of 15 Graves disease patients, 7 of 15 (47%) achieved clinical response and biochemical euthyroidism without rescue antithyroid drugs.
3
Iscalimab rapidly and significantly reduced serum CXCL13 concentrations (P < 0.001), a biomarker associated with B-cell activity.
4
Iscalimab was generally safe: 12 of 15 (80%) patients reported at least one adverse event, all treatment-related events were mild or moderate and resolved by study end.
5
Iscalimab, a human blocking nondepleting anti-CD40 monoclonal antibody, achieved complete CD40 engagement for up to 20 weeks after treatment.
6
Thyroid hormones (free and total T3 and T4) normalized in the 7 responders who did not receive rescue medication; TSH normalized in 2 of 15 (13.3%).
7
Thyroperoxidase and thyroglobulin autoantibodies decreased significantly in treatment responders.
8
Thyrotropin receptor autoantibodies (TSH-R-Ab) declined significantly across all patients (mean 15.3 IU/L to 4.0 IU/L, 66% reduction; P < 0.001), normalizing in 4 patients (27%).
Research Object
Iscalimab (a human, blocking, nondepleting anti-CD40 monoclonal antibody) administered to patients with Graves hyperthyroidism
Research Subject
Efficacy and safety of iscalimab for controlling hyperthyroidism in Graves disease, including effects on thyroid hormones, thyroid autoantibodies (TSH-R-Ab, TPO, Tg), CD40 engagement, CXCL13 levels, pharmacokinetics, and adverse events
Publication Details
Publication Date
2019-09-12
Journal
Publisher
ISSN
Cited by
100
Access Type
Author Information
Download PDF
Subscribe to digest